Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.50 |
| ▸ | FAP | Q12884 | 11/20 | 0.48 |
| ▸ | PREP | P48147 | 7/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.48 |
| ▸ | PITRM1 | Q5JRX3 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997344 | 0.82 | MEN1 (0.45) | DPP4 | |
| SCHEMBL8287679 | 0.78 | DPP4 (0.67) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL3179037 | 0.78 | DPP4 (0.67) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL16104907 | 0.78 | DPP4 (0.67) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL8287685 | 0.75 | DPP4 (0.65) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL13347125 | 0.75 | DPP4 (0.65) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL3195160 | 0.75 | DPP4 (0.65) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL13347217 | 0.72 | DPP4 (0.46) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL13372088 | 0.71 | FAP (0.49) | DPP4FAPPREPDPP9DPP8 | |
| SCHEMBL8287953 | 0.71 | HRH3 (0.56) | DPP4FAPPREPDPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1997533-B1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | PHENOMIX CORP (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-1689757-B1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORP (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 269/4885PREP 118/4885 |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 238/4885PREP 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.